

## **COL4A6 Polyclonal Antibody**

Catalog No: YT1029

Reactivity: Human

**Applications:** WB;IHC;IF;ELISA

Target: COL4A6

**Fields:** >>PI3K-Akt signaling pathway;>>Focal adhesion;>>ECM-receptor

interaction;>>Relaxin signaling pathway;>>AGE-RAGE signaling pathway in

diabetic complications;>>Protein digestion and

absorption;>>Amoebiasis;>>Human papillomavirus infection;>>Pathways in

cancer;>>Small cell lung cancer

Gene Name: COL4A6

Protein Name: Collagen alpha-6(IV) chain

Q14031

Human Gene Id: 1288

**Human Swiss Prot** 

No:

Immunogen: The antiserum was produced against synthesized peptide derived from human

Collagen IV alpha6. AA range:1201-1250

**Specificity:** COL4A6 Polyclonal Antibody detects endogenous levels of COL4A6 protein.

**Formulation :** Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source: Polyclonal, Rabbit, IgG

**Dilution:** WB 1:500 - 1:2000. IHC 1:100 - 1:300. IF 1:200 - 1:1000. ELISA: 1:40000. Not

yet tested in other applications.

**Purification:** The antibody was affinity-purified from rabbit antiserum by affinity-

chromatography using epitope-specific immunogen.

Concentration: 1 mg/ml

1/3



-15°C to -25°C/1 year(Do not lower than -25°C) **Storage Stability:** 

Observed Band: 160kD

Focal adhesion; ECM-receptor interaction; Pathways in cancer; Small cell lung **Cell Pathway:** 

cancer;

This gene encodes one of the six subunits of type IV collagen, the major **Background:** 

structural component of basement membranes. Like the other members of the

type IV collagen gene family, this gene is organized in a head-to-head

conformation with another type IV collagen gene, alpha 5 type IV collagen, so that the gene pair shares a common promoter. Deletions in the alpha 5 gene that extend into the alpha 6 gene result in diffuse leiomyomatosis accompanying the Xlinked Alport syndrome caused by the deletion in the alpha 5 gene. Alternative splicing results in multiple transcript variants encoding different isoforms.

[provided by RefSeq, Dec 2013],

**Function:** disease: Deletions covering the N-terminal regions of COL4A6 and COL4A5,

which are localized in a head-to-head manner, are the cause of diffuse

leiomyomatosis with Alport syndrome (DL-ATS) [MIM:308940]; also known as esophageal and vulval leiomyomatosis with nephropathy or Alport syndrome and diffuse leiomyomatosis (ATS-DL). DL-ATS is the combination of Alport syndrome

(AS) and diffuse leiomyomatosis (DL). AS is characterized by progressive glomerulonephritis, often associated with high-tone sensorineural deafness, specific eye abnormalities (lenticonous and macular flecks), and glomerular basement membrane defects. DL is a tumorous process involving smooth muscle cells, mostly of the esophagus, but also of the tracheobronchial tree and the

female genital tract., domain: Alpha chains of type IV collagen have a non-

collagenous domain (NC1) at their C-terminus, frequent interruptions of the G


Subcellular Location:

Secreted, extracellular space, extracellular matrix, basement membrane.


Eye, Kidney, Prostate, **Expression:** 

## **Products Images**


2/3



Western Blot analysis of various cells using COL4A6 Polyclonal Antibody diluted at 1:500



Immunofluorescence analysis of HeLa cells, using Collagen IV alpha6 Antibody. The picture on the right is blocked with the synthesized peptide.



Immunohistochemistry analysis of paraffin-embedded human cervix carcinoma tissue, using Collagen IV alpha6 Antibody. The picture on the right is blocked with the synthesized peptide.